Saginala K, Barsouk A, Aluru JS, Rawla P, Barsouk A. Epidemiology of melanoma. Med Sci. 2021;9(4):63. https://doi.org/10.3390/medsci9040063.

Article  Google Scholar 

Sloan E, Nock CJ, Einstein DB. Diagnosis and treatment of mela-noma brain metastasis: a literature review. Cancer Control. 2009;16(3):248–55. https://doi.org/10.1177/107327480901600307.

Article  PubMed  Google Scholar 

Cagney DN, et al. Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study. Neuro Oncol. 2017;19(11):1511–21. https://doi.org/10.1093/neuonc/nox077.

Article  PubMed  PubMed Central  Google Scholar 

Vosoughi E, Lee JM, Miller JR, et al. Survival and clinical outcomes of patients with melanoma brain metastasis in the era of checkpoint inhibitors and targeted therapies. BMC Cancer. 2018;18(1):490. https://doi.org/10.1186/s12885-018-4374-x.

Article  PubMed  PubMed Central  Google Scholar 

Wolfram M, Samlowski E, Julian M, Wu K. Management of brain metastases in melanoma. UpToDate Website

Steininger J, et al. Leptomeningeal metastases in melanoma patients: an update on and future perspectives for diagnosis and treatment. Int J Mol Sci. 2023;24(14):11443. https://doi.org/10.3390/ijms241411443.

Article  PubMed  PubMed Central  Google Scholar 

Le Rhun E, et al. EANO–ESMO clinical practice guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours. Ann Oncol. 2017;28:iv84–99. https://doi.org/10.1093/annonc/mdx221.

Article  PubMed  Google Scholar 

Khaled ML, Tarhini AA, Forsyth PA, Smalley I, Piña Y. Leptomeningeal disease (LMD) in patients with melanoma metastases. Cancers (Basel). 2023;15(6):1884. https://doi.org/10.3390/cancers15061884.

Article  PubMed  Google Scholar 

Akbani R, et al. Genomic classification of cutaneous melanoma. Cell. 2015;161(7):1681–96. https://doi.org/10.1016/j.cell.2015.05.044.

Article  Google Scholar 

Jakob JA, et al. NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer. 2012;118(16):4014–23. https://doi.org/10.1002/cncr.26724.

Article  PubMed  Google Scholar 

Davies H, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417(6892):949–54. https://doi.org/10.1038/nature00766.

Article  PubMed  Google Scholar 

Curtin JA, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med. 2005;353(20):2135–47. https://doi.org/10.1056/NEJMoa050092.

Article  PubMed  Google Scholar 

Eroglu Z, Ribas A. Combination therapy with BRAF and MEK inhibitors for melanoma: latest evidence and place in therapy. Ther Adv Med Oncol. 2016;8(1):48–56. https://doi.org/10.1177/1758834015616934.

Article  PubMed  PubMed Central  Google Scholar 

Sosman JA, et al. Survival in BRAF V600–mutant advanced melanoma treated with vemurafenib. N Engl J Med. 2012;366(8):707–14. https://doi.org/10.1056/NEJMoa1112302.

Article  PubMed  PubMed Central  Google Scholar 

Subbiah V, Baik C, Kirkwood JM. Clinical development of BRAF plus MEK inhibitor combinations. Trends Cancer. 2020;6(9):797–810. https://doi.org/10.1016/j.trecan.2020.05.009.

Article  PubMed  Google Scholar 

Harding JJ, et al. A retrospective evaluation of vemurafenib as treatment for BRAF-mutant melanoma brain metastases. Oncologist. 2015;20(7):789–97. https://doi.org/10.1634/theoncologist.2014-0012.

Article  PubMed  PubMed Central  Google Scholar 

Gorka E, Fabó D, Gézsi A, Czirbesz K, Fedorcsák I, Liszkay G. Dabrafenib therapy in 30 patients with melanoma metastatic to the brain: a single-centre controlled retrospective study in Hungary. Pathol Oncol Res. 2018;24(2):401–6. https://doi.org/10.1007/s12253-017-0256-9.

Article  PubMed  Google Scholar 

Dzienis MR, Atkinson VG. Response rate to vemurafenib in patients with B-RAF-positive melanoma brain metastases. Melanoma Res. 2014;24(4):349–53. https://doi.org/10.1097/CMR.0000000000000068.

Article  PubMed  Google Scholar 

Martin-Algarra S, et al. Effectiveness of dabrafenib in the treatment of patients with BRAF V600–mutated metastatic melanoma in a Named Patient Program. Melanoma Res. 2019;29(5):527–32. https://doi.org/10.1097/CMR.0000000000000608.

Article  PubMed  Google Scholar 

Long GV, et al. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol. 2012;13(11):1087–95. https://doi.org/10.1016/S1470-2045(12)70431-X.

Article  PubMed  Google Scholar 

Hauschild, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012;380(9839):358–65. https://doi.org/10.1016/S0140-6736(12)60868-X.

Article  PubMed  Google Scholar 

Flaherty KT, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med. 2012;367(18):1694–703. https://doi.org/10.1056/NEJMoa1210093.

Article  PubMed  PubMed Central  Google Scholar 

GeukesFoppen MH, Boogerd W, Blank CU, van Thienen JV, Haanen JB, Brandsma D. Clinical and radiological response of BRAF inhibition and MEK inhibition in patients with brain metastases from BRAF-mutated melanoma. Melanoma Res. 2018;28(2):126–33. https://doi.org/10.1097/CMR.0000000000000429.

Article  Google Scholar 

Drago JZ, et al. Clinical experience with combination BRAF/MEK inhibitors for melanoma with brain metastases: a real-life multicenter study. Melanoma Res. 2019;29(1):65–9. https://doi.org/10.1097/CMR.0000000000000527.

Article  PubMed  Google Scholar 

Holbrook K, et al. Intracranial antitumor activity with encorafenib plus binimetinib in patients with melanoma brain metastases: a case series. Cancer. 2020;126(3):523–30. https://doi.org/10.1002/cncr.32547.

Article  PubMed  Google Scholar 

Long GV, et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet. 2015;386(9992):444–51. https://doi.org/10.1016/S0140-6736(15)60898-4.

Article  PubMed  Google Scholar 

Robert C, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 2015;372(1):30–9. https://doi.org/10.1056/NEJMoa1412690.

Article  PubMed  Google Scholar 

Davies MA, et al. Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial. Lancet Oncol. 2017;18(7):863–73. https://doi.org/10.1016/S1470-2045(17)30429-1.

Article  PubMed  PubMed Central  Google Scholar 

Dummer R, et al. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF -mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2018;19(5):603–15. https://doi.org/10.1016/S1470-2045(18)30142-6.

Article  PubMed  Google Scholar 

R. Team. Encorafenib (Braftovi) in combination with binimetinib (Mektovi). Can J Health Technol. 2021;1(7):1. https://doi.org/10.51731/cjht.2021.107.

Article  Google Scholar 

Ahmed KA, et al. LINAC-based stereotactic radiosurgery to the brain with concurrent vemurafenib for melanoma metastases. J Neurooncol. 2015;122(1):121–6. https://doi.org/10.1007/s11060-014-1685-x.

Article  PubMed  Google Scholar 

Larkin J, et al. Combined vemurafenib and cobimetinib in BRAF -mutated melanoma. N Engl J Med. 2014;371(20):1867–76. https://doi.org/10.1056/NEJMoa1408868.

Article  PubMed  Google Scholar 

Ascierto PA, et al. Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study. Lancet Oncol. 2023;24(1):33–44. https://doi.org/10.1016/S1470-2045(22)00687-8.

Article  PubMed  Google Scholar 

Cai C, Yunusa I, Tarhini A. Estimated cost-effectiveness of atezolizumab plus cobimetinib and vemurafenib for treatment of BRAF V600 variation metastatic melanoma. JAMA Netw Open. 2021;4(11): e2132262. https://doi.org/10.1001/jamanetworkopen.2021.32262.

Article  PubMed  PubMed Central  Google Scholar 

• Dummer R, et al. Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2023. https://doi.org/10.1016/S1470-2045(23)00334-0. This study demonstrated that triplet combination therapy with atezolizumab plus vemurafenib plus cobimetinib provided intracranial activity in patients with BRAFV600-mutated melanoma and CNS metastases.

Long GV, et al. Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. Lancet Oncol. 2018;19(5):672–81. https://doi.org/10.1016/S1470-2045(18)30139-6.

Article  PubMed  Google Scholar 

Hodi FS, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–23. https://doi.org/10.1056/NEJMoa1003466.

Article  PubMed  PubMed Central  Google Scholar 

Margolin K, et al. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol. 2012;13(5):459–65. https://doi.org/10.1016/S1470-2045(12)70090-6.

Article  PubMed  Google Scholar 

Kluger HM, et al. Long-term survival of patients with melanoma with active brain metastases treated with pembrolizumab on a phase II trial. J Clin Oncol. 2019;37(1):52–60. https://doi.org/10.1200/JCO.18.00204.

Article